Immatics NV (IMTX) Quote

Agree, else they would not file a news for this...

IMTX: Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024

( this looks like a highly important presentation, imo)


https://immatics.com/
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-concept clinical data for its next-generation, half-life extended TCR Bispecific molecule, TCER® IMA401 (MAGEA4/8), will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 on Monday, September 16, 2024 at 11:25 CEST.

Full abstracts will be available on the ESMO website on Monday, September 9, 2024, at 00:05 CEST.

Oral presentation

Date / Time: September 16, 2024 / 11:25 CEST
Session: Investigational Immunotherapy
Title: Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation
Presenting author: Martin Wermke, MD (University Hospital Dresden, Germany)
Room: Granada Auditorium - Hall 6

About IMA401

IMA401 is Immatics’ most advanced TCER® molecule that targets an HLA-A*02-presented (human leukocyte antigen) peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 (“MAGEA4/8”). The MAGEA4/8 peptide has been identified and validated by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT® and is presented at a 5-fold higher copy number per tumor cell than the MAGEA4 peptide targeted in other clinical trials. Following preclinical proof-of-concept data, including complete remissions of transplanted human-derived tumors in xenograft mouse models, the Phase 1 trial investigates IMA401 in patients with tumors of high MAGEA4/8 prevalence, such as squamous non-small cell lung carcinoma (sqNSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), bladder, uterine, esophageal and ovarian carcinomas, as well as melanoma, sarcoma subtypes and other solid cancer types.

About TCER®

Immatics’ next-generation half-life extended TCER® molecules are antibody-like “off-the-shelf” biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing a specific tumor target. The design of the TCER® molecules enables the activation of any T cell in the body to attack the tumor, regardless of the T cells’ intrinsic specificity. Immatics proprietary biologics are engineered with two binding regions: a TCR domain and a T cell recruiter domain. The TCER® format is designed to maximize efficacy while minimizing toxicities in patients. It contains a high-affinity TCR domain that is designed to bind specifically to the cancer target peptide on the cell surface presented by an HLA molecule. The antibody-derived, low-affinity T cell recruiter domain is directed against the TCR/CD3 complex and recruits a patient’s T cells to the tumor to attack the cancer cells. With a low-affinity recruiter aiming for optimized biodistribution and enrichment of the molecule at the tumor site instead of the periphery, TCER® are engineered to reduce the occurrence of immune-related adverse events, such as cytokine release syndrome. In addition, the TCER® format consists of an Fc-part conferring half-life extension, stability, and manufacturability. TCER® are “off-the-shelf” biologics and thus immediately available for patient treatment. They can be distributed through standard pharmaceutical supply chains and provide the opportunity to reach a large patient population without the need for specialized medical centers.

About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.

https://finance.yahoo.com/news/immatics-announces-upcoming-oral-presentation-130000787.html

That all sounds good!
I hope tomorrow we will see a move like Friday...

IMTX: Immatics (NASDAQ:IMTX) Price Target Raised to $16.00

https://www.americanbankingnews.com/2024/05/20/immatics-nasdaqimtx-price-target-raised-to-16-00.html

As an additional note, Amgen's Imdelltra had also received "accelerated approval" status, however i have not researched the specifics of when and under what program.

Would be worth to investigate, imo

https://finance.yahoo.com/news/fda-approves-imdelltra-tarlatamab-dlle-224500427.html

I concur with all of your thoughts as well.

I'm actually surprised we have not heard anything yet on IMA203 trial progress / FDA approval for path forward.

I noticed Amgen received FDA approval for a Bi-specific T-engager, that was a surprise as i wasn't aware that Amgen was involved with T-TCR tech.
Bodes well for Immatics, imo

Here is the story on Amgen:

https://finance.yahoo.com/news/fda-approves-imdelltra-tarlatamab-dlle-224500427.html

Something appears to be up today!

IMA402 was updated as of May 24 - no major changes, locations etc.

https://classic.clinicaltrials.gov/ct2/history/NCT05958121?A=1&B=13&C=merged#StudyPageTop

Interesting! Thank u!
I'm very optimistic IMTX is on a good path!
I wonder a little bit about the course. I would say we should be at 20 th right now.
Perhaps some shortseller try to keep it a little bit down...But this will change in the near future - IMO.
If IMA203 gets admission by FDA WE should very quickly see 30-50...

IMTX: Institutional Holders March 31/24

https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings

Of interest:

Rtw Investments, Lp - 10,000,000 shares held as of March 31/24

https://www.rtwfunds.com

IMTX: May/24 company presentation

https://www.sec.gov/Archives/edgar/data/1809196/000119312524137708/d799994dex993.htm

IMTX: Form 6-K filed May14/24

https://www.sec.gov/Archives/edgar/data/1809196/000119312524137708/d799994d6k.htm

Consolidated Financial Statements for the three-month period ended March 31, 2024

https://www.sec.gov/Archives/edgar/data/1809196/000119312524137708/d799994dex991.htm

IMTX: interesting AH volume/trade

https://www.nasdaq.com/market-activity/stocks/imtx/after-hours

IMTX: Article of interest:

https://markets.businessinsider.com/news/stocks/maintained-buy-rating-for-immatics-amid-robust-clinical-pipeline-and-promising-partnerships-1033208122

Next takeover in the biotech sector...

https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition

Thank u! Very interesting. I would like to see some higher levels in the PPS before something like M&A....
But perhaps interesting times coming...

IMTX: S/A Article of Interest:

https://seekingalpha.com/news/4077812-patent-cliffs-could-fuel-increased-ma-in-oncology-this-year-cantor-says

Cantor sees strong year ahead for oncology M&A
Mar. 10, 2024 12:08 PM ETKura Oncology, Inc. (KURA) Stock, BCYC Stock, IMCR Stock, ALXO Stock, CGON StockJNJ, NVS, BMY, PFE, MRK, EXEL, GERN, FUSN, VSTM, KPTI, SNDX, MRUS, URGN, DCPH, MOR, ARVN, HARP, IDYA, SWTX, RVMD, ORIC, ZNTL, LEGN, RLAY, IMTX, PMVP, OLMA, DAWN, JANX, AMAM, ERAS, NUVLBy: Val Brickates Kennedy, SA News Editor9 Comments
Chessboard with chess pieces and wooden blocks with the word mergers and acquisitions
cagkansayin

Cantor Fitzgerald sees another strong year ahead for oncology M&A, with companies focused on antibody drug conjugates, radiopharmaceuticals and T-cell engagers expected to attract increased attention from major drugmakers looking to replenish pipelines.

Impending patent cliffs will be a big motivator for deals. According to Cantor, around $182B in revenue is at risk over the next four years due to patent expirations, with oncology products accounting for 42% of that number.

Several of the industry's biggest are set to lose patent protection by 2029, including Bristol Myers (BMY) Yervoy, Pomalyst and Opdivo; Johnson & Johnson’s (JNJ) Imbruvica; Merck’s (MRK) Keytruda; Pfizer’s (PFE) Ibrance; and Roche’s (OTCQX:RHHBY) Perjeta, according to Cantor.

Meanwhile, the global market for oncology drugs is expected to grow from $180B in 2022 to $323B in 2028, a rate that is “unparalleled to other therapeutics areas,” Cantor said. In comparison, the global biopharmaceutical market is expected to swell from $978B in 2022 to $1.39T in 2028.

Cantor estimates the industry should see between five and 17 acquisition deals this year, noting that three have already been announced to date: J&J/Ambrx (AMAM), Merck/Harpoon (HARP), and Novartis (NVS)/Morphosys (MOR).

The investment bank also pointed out that the pool of potential buyers is fairly deep as pretty much every major drugmaker has a presence in oncology, with Novo Nordisk (NVO) being a notable exception.

So what type of assets will Big Pharma be seeking out?

Cantor still sees a preference for de-risked assets but noted that proof-of-concept data for oncology drugs can often be achieved in Phase 1/2 testing. Drug candidates addressing larger markets, such as breast, lung or colorectal cancer, should be particularly attractive to potential buyers.

While small molecule candidates will probably account for around 50% of the deals, Cantor says complex biologics have been gaining in popularity. The bank sees assets such as antibody drug conjugates, radiopharmaceuticals and T-cell engagers as being particularly attractive acquisition targets this year, while synthetic lethality and TCR therapies could also see increased interest.

Cantor sees several companies in its coverage universe as potentially attracting suitors this year, including Kura (NASDAQ:KURA), Bicycle (NASDAQ:BCYC), Immunocore (NASDAQ:IMCR), ALX Oncology (NASDAQ:ALXO), Arvinas (ARVN), Immatics (IMTX), Verastem (VSTM), Oric (ORIC), and CG Oncology (NASDAQ:CGON).

Potential targets outside of its coverage include Day One (DAWN), Deciphera (DCPH), Erasca (ERAS), Exelixis (EXEL), Fusion (FUSN), Geron (GERN), Ideaya (IDYA), Karyopharm (KPTI), Janux (JANX), Legend Biotech (LEGN), Merus (MRUS), Nuvalent (NUVL), Olmea (OLMA), PMV (PMVP), Relay Therapeutics(RLAY), Revolution Medicines (RVMD), Syndax (SNDX), SpringWorks Therapeutics (SWTX), UroGen (URGN), and Zentalis (ZNTL).

Chart looking much better now. IMO good chance to leave these levels now and climb to 20th...

I don't think there is a set timeline for FDA approval, once RMAT designation is received.

Combining RMAT with Accelerated Approval and Priority Review would greatly reduce the timeline for approval and to reach the market.

Article of Interest regarding RMAT:

https://www.pharmacytimes.com/view/regenerative-medicine-advanced-therapy-the-latest-special-fda-designation

I'm actually expecting a press release tomorrow morning. Day 2 = February 28/24

https://cartcr-europe.com/seminar/clinical-activity-of-ima203-tcr-t-targeting-prame-in-melanoma-beyond/

Tomorrow's session includes a clinical update on IMA 203

Interesting that they chose London to provide the clinical update.

imo,

today's session:

https://cartcr-europe.com/seminar/accelerating-analytical-testing-to-facilitate-rapid-product-release-decrease-end-to-end-production-time/
would probably be in reference to their manufacturing facility in Houston.


Remember they received RMAT designation for IMA203 - announced October24/23.

https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/92348626/immatics-receives-fda-regenerative-medicine-advanc

They never announced an IND enabling Phase 2 trial yet. No updates since October 25/23

https://classic.clinicaltrials.gov/ct2/history/NCT03686124?A=1&B=22&C=merged#StudyPageTop

New data should come soon:

New Clinical Data From:

IRCCS Bambino Gesu Children’s Hospital, Immatics, Caribou Biosciences, Carisma Therapeutics, and Kyverna Therapeutics

https://cartcr-europe.com/

February 27-29, 2024

Hello

StemPoint Capital LLC - new investor of interest

https://www.businesswire.com/news/home/20230119005659/en/StemPoint-Capital-Announces-Strategic-Relationship-with-Leucadia-Asset-Management

https://leucadia-am.com/investment_offerings/stempoint-capital/

IMTX: Institutional Holdings for Dec.31/23 just starting to come in:

Significant increases to date, at Wellington / Woodline / Goldman Sachs / Stempoint - new investor/ complete listing here:

https://www.nasdaq.com/market-activity/stocks/imtx/institutional-holdings

Novartis wants to buy Morphosys...
Interesting is - Immatics and Morphosys and Novartis seem to have connections, too.
Perhaps it's only the beginning of a bigger consolidation in the sector.

https://www.labiotech.eu/trends-news/leading-german-biotechs-morphosys-and-immatics-partner-to-pump-up-their-immuno-oncology-therapies/

Sectors
Drug Development
More
Podcast
Reports
Home News and Trends
Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies
By Philip Hemme
2 mins
August 25, 2015
Updated
:
August 4, 2021
Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens.

They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 distinct drugs in research and development and is worth €1.67Bn. Tübingen-based Immatics owns the leading target discovery platform in cancer immunotherapy and raised over €120M. And now they want to team up. What a match!

Here’s how they want to tackle cancer: Tumor cells contain specific peptides that are not present in healthy cells. These are presented on the surface through specialized receptors, so-called major histocompatibility complex (MHC) receptors. The collaboration between Immatics and MorphoSys aims to discover antibodies against these MHC-bound peptide targets in order to kill the tumor cells.

Within the collaboration, MorphoSys gets several tumor-associated peptides that were discovered using Immatics’ platform. These are present in a number of solid and hematological cancers and can be used as antibody targets.

In return, Immatics will be provided with some of MorphoSys’ antibodies against a number of its discovered peptides. The companies will pay each other undisclosed milestones as well as royalties on marketed products.

The partnering is especially valuable for MorphoSys. It had to sustain a major drop of its stock after Celgene had abandoned the company. Since then, both collaborations with Novartis and Heptares Therapeutics advanced. With all these good news, MorphoSys stock slowly recovers.

The merging could pave the way for a leading immuno-oncology player, from which the whole biotech ecosystem could profit.

Bonus, we interviewed the CEO of Immatics Paul Higham during our South German Tour. Here’s the video:

Please accept cookies to access this content


Immatics – Paul Higham, CEO from LabiotechTour on Vimeo.

Interesting!
Think ist's important now to leave the 52 week range and to climb about 13.14....after that it could quickly go to 15 and more...

IMTX: Options activity of interest:

Sizeable open interest on Feb 16 calls with strike price of $15 and $17.5 as a point of information.

(unable to post chart)

IMTX: Presentation February 11-14 at SCOPE 24

https://investors.immatics.com/events-presentations

https://www.scopesummit.com

Thanks! Everything looking promising here. Hope some big Investors will soon come in...

BIOTECHTV video : TCR discussion starts around 15:30 mark of this video - Cantor Fitzgerald

https://www.biotechtv.com/post/eric-schmidt-cantor-fitzgerald-january-22-2024

IMTX: New Presentation - January 22, 2024 ( filed as an exhibit)

https://www.sec.gov/Archives/edgar/data/1809196/000095010324000955/dp205494_ex9903.htm

IMTX: Sec filing regarding recent offering / capital raise - interesting exhibits

https://www.sec.gov/Archives/edgar/data/1809196/000095010324000955/dp205494_6k.htm

This puts the O/S (Outstanding Shares) in and around 100 million.

Theory = Internal squabbling and IMTX is buying out dissenting shareholders.

IMTX: Immatics Announces Pricing of $175 Million Public Offering

https://www.globenewswire.com/news-release/2024/01/18/2811206/0/en/Immatics-Announces-Pricing-of-175-Million-Public-Offering.html

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $175 million. The offering is expected to close on January 22, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,388,750 additional shares at the public offering price, less the underwriting discount.

Jefferies, BofA Securities and Leerink Partners are acting as joint book-running managers for the offering.

A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on August 9, 2021. The offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained free of charge from

Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821-7388, email: Prospectus_Department@Jefferies.com;
BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, telephone: (800) 294-1322, email: dg.prospectus_requests@bofa.com;
Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, email: syndicate@leerink.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

IMTX: recent short report:

https://www.marketbeat.com/stocks/NASDAQ/IMTX/short-interest/

2 million plus increase in short position December 15/23 - December 31/23

"Thanks".... IMTX management

IMTX: https://www.sec.gov/Archives/edgar/data/1809196/000119312524009253/d127760d424b5.htm#supptoc127760_6

Not sure what to think of this. Biggest question, at the moment imo, is why the capital raise when they have enough cash on hand and just received 120 million from Moderna?

Probably tanking tomorrow.

Interesting find! It seem's to me something will happen here in the near future...

Nice volume again!

January 9/25 3:07 ET Level II Ask looking thin, at the moment, especially above $12.25

Volume/Price - on FIRE!!

Sumthing go'ing on at JP Morgan conference??

IMTX: Clinical Trial Review:

1. NCT05958121 IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/?or Refractory Solid Tumors
https://clinicaltrials.gov/study/NCT05958121?spons=immatics&rank=3&tab=table

2. NCT05359445 IMA401 TCER® in Recurrent and/?or Refractory Solid Tumors
https://clinicaltrials.gov/study/NCT05359445?spons=immatics&rank=4&tab=table

3. NCT03686124 ACTengine® IMA203/?IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/?or Refractory Solid Tumors (ACTengine)
https://clinicaltrials.gov/study/NCT03686124?spons=immatics&rank=6&tab=table

Of interest is that all 3 have Data Monitoring Committees

https://www.ppd.com/wp-content/uploads/2020/07/decision-tree-graphic.pdf

IMTX: Immatics to attend meetings at the 42nd Annual J.P. Morgan Healthcare Conference January 8-11/24

https://investors.immatics.com/events-presentations

Immatics Announces Third Quarter 2023 Financial Results and Business Update...

8.30 am conference call....

IMTX: Form 6-k

https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/92498872/form-6-k-report-of-foreign-issuer-rules-13a-16

EXCERPT 1:


Development path for IMA203 GEN1 and IMA203CD8 GEN2 monotherapies



The goal of Immatics’ development strategy is to make its cell therapies targeting PRAME available to the broadest possible solid cancer patient population with an initial focus on the US market. To achieve this, Immatics has announced a three-step development strategy for leveraging the full breadth of PRAME, a target that is highly expressed in various solid cancers.



1. Focus on IMA203 GEN1 in cutaneous melanoma (potentially bundled with uveal melanoma), targeted to enter a registration-enabling Phase 2 clinical trial in 2024. Discussions with FDA to align on patient population, clinical trial design and CMC aspects are ongoing under the RMAT designation achieved for IMA203 GEN1 in multiple cancer types including cutaneous and uveal melanoma. There are up to 3,300 HLA-A*02 and PRAME-positive cutaneous and


Immatics Press Release November 8, 2023 5 | 8


uveal melanoma last-line patients per year in the US. A next update on the clinical development plan is expected in the first quarter of 2024.



2. In parallel, commence dedicated dose expansion cohorts for signal finding in ovarian and uterine cancer, preferentially with IMA203CD8 GEN2. Enrollment of patients with these cancer types is already ongoing. There are up to 9,000 HLA-A*02 and PRAME-positive ovarian and uterine last-line cancer patients per year in the US.


3. The development of a broader tumor-agnostic label in PRAME+ solid cancers, including in NSCLC, triple-negative breast cancer, and others. This could leverage the full potential of PRAME across multiple solid cancer types.

IMTX: Press Release Nov.8/23

https://finance.yahoo.com/news/immatics-reports-interim-clinical-data-120000187.html

Interim clinical data out...

Thank u! Seems to have the knowledge in the sector...
Hope to see another nice day with buying pressure...

IMTX: New analyst coverage from Cantor Fitzgerald.

https://www.streetinsider.com/New+Coverage/Cantor+Fitzgerald+Starts+Immatics+%28IMTX%29+at+Overweight/22349384.html?classic=1

Articles on Eric Schmidt:

https://endpts.com/former-allogene-cfo-eric-schmidt-talks-about-his-new-role-at-cantor-and-the-future-of-cell-therapies/

https://biotuesdays.com/2023/09/06/cantor-boosts-biotech-research-with-josh-schimmer-eric-schmidt/

( all are subscription articles)

I agree. Within the next days/weeks we should hear something.
That would be great. In that case we would quickly climb above 50 and more...

I concur, sentiment reversal with buying pressure now.

According to the latest presentation, should be a clinical update in Q4/23 in IMA203 - ref. page 27

https://investors.immatics.com/static-files/0df36fcf-308b-4e29-afe7-c83c562abab6

Also, if you put the latest press release regarding RMAT designation for IMA203 into the context of the above presentation, FDA approval of IMA203 is a possibility in 2024, imo.
( that could be taken as a bold statement, however, imo IMTX is doing an awesome job in all departments.)

RMAT Press Release:
https://investors.immatics.com/news-releases/news-release-details/immatics-receives-fda-regenerative-medicine-advanced-therapy-0